Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company has operations in pharmaceutical, animal health, and consumer care.
Website: merck.com


  • Good financial results growth rate 1 335.3% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (8.0%)
  • Dividend yield for the last twelve months 2.6%
  • Free cash flow yield -1.9% (LTM)
  • Share price is 63.6% higher than minimum and 11.8% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (-86.9x vs
    )

Key Financials (Download financials)

Ticker: MRK
Share price, USD:  (+1.2%)117.295
year average price 118.12  


year start price 107.82 2023-09-18

min close price 100.18 2023-11-28

max close price 132.96 2024-06-24

current price 115.86 2024-09-16
Common stocks: 2 528 810 012

Dividend Yield:  2.6%
FCF Yield LTM: -1.9%
EV / LTM EBITDA: -86.9x
EV / EBITDA annualized: 11.1x
Last revenue growth (y/y):  +8.9%
Last growth of EBITDA (y/y):  +200.0%
Historical revenue growth:  +9.1%
Historical growth of EBITDA:  +6.9%
Target EV / EBITDA (hist percentile):
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 296 617
Net Debt ($m): 26 140
EV (Enterprise Value): 322 757
EBITDA LTM ($m): -3 715
EV / LTM EBITDA: -86.9x
Price to Book: 6.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2024-09-14fool.com

Where Will Merck Stock Be in 5 Years?

2024-09-14businesswire.com

KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma

2024-09-14seekingalpha.com

Merck Appears Ready To Return To June Highs (Technical Analysis)

2024-09-13zacks.com

Merck (MRK) Increases Yet Falls Behind Market: What Investors Need to Know

2024-09-12zacks.com

Here's Why Merck (MRK) Gained But Lagged the Market Today

2024-09-10zacks.com

MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study

2024-09-09zacks.com

Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?

2024-09-09marketwatch.com

Summit Therapeutics' stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trial

2024-09-09barrons.com

Merck Stock Falls After Rival Beats Keytruda Cancer Drug in Trial

2024-09-06seekingalpha.com

Merck & Co., Inc. (MRK) CEO Rob Davis presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data